Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-18-054196
Filing Date
2018-10-04
Accepted
2018-10-04 12:01:38
Documents
2
Period of Report
2018-10-02

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1621
2 POA DOCUMENT poa.txt EX-24.3_812736 4104
  Complete submission text file 0001209191-18-054196.txt   7279
Mailing Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804
Business Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804 5109706000
SANGAMO THERAPEUTICS, INC (Issuer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O SANGAMO THERAPEUTICS, INC. POINT RICHMOND TECH CTR, 501 CANAL BLVD. RICHMOND CA 94804
Business Address
Boissel Stephane (Reporting) CIK: 0001755198 (see all company filings)

Type: 3 | Act: 34 | File No.: 000-30171 | Film No.: 181107350